Avadel Pharmaceuticals Valuation

Is AWK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AWK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AWK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AWK's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AWK?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AWK. This is calculated by dividing AWK's market cap by their current preferred multiple.
What is AWK's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$1.22b

AWK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.5x
Enterprise Value/EBITDA	-12.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AWK's PS Ratio compare to its peers?

The above table shows the PS ratio for AWK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.5x
DMP Dermapharm Holding	1.6x	3.8%	€1.9b
PSG PharmaSGP Holding	2.3x	6.8%	€256.6m
ASZ1 Alimera Sciences	2.9x	11.4%	€257.0m
93M1 MPH Health Care	3x	6.0%	€104.5m
AWK Avadel Pharmaceuticals	12.7x	30.7%	€1.2b

Price-To-Sales vs Peers: AWK is expensive based on its Price-To-Sales Ratio (12.7x) compared to the peer average (2.5x).

Price to Earnings Ratio vs Industry

How does AWK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: AWK is expensive based on its Price-To-Sales Ratio (12.7x) compared to the European Pharmaceuticals industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is AWK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AWK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AWK's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AWK forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€11.30	€21.59 +91.1%	11.0%	€26.20	€18.07	n/a	10
Sep ’25	€13.20	€21.50 +62.9%	11.0%	€26.09	€17.99	n/a	10
Aug ’25	€15.10	€21.74 +44.0%	11.2%	€26.66	€18.39	n/a	10
Jul ’25	€12.90	€21.95 +70.2%	11.2%	€26.92	€18.56	n/a	10
Jun ’25	€14.30	€21.95 +53.5%	11.2%	€26.92	€18.56	n/a	10
May ’25	€16.30	€21.04 +29.1%	2.2%	€21.51	€20.58	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.